Intravenous administration of a humanized NGF neutralizing monoclonal antibody (tanezumab) in IC/BPS patients demonstrated proof of concept by improving the global response assessment and reducing the urgency episodes (92). The gene discussed is NGF; the disease is Bartsocas-Papas syndrome 1.